Clinical trials: Overweight and Obesity
Obesity
A Study on Efficacy and Safety of Topiramate in the Treatment of Patients With Obesity
The purpose of this study is to compare the efficacy and safety of topiramate (96, 192, and 256mg daily) with placebo in long-term treatment of obesity.
- Trial name
- NCT00236639
- Testing
- topiramate
- Volunteers
- 1,293 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Obesity
Persons With Obesity (PwO) Exploratory Research
The purpose of this study is to understand the personal flow along the weight loss management journey. A range of variables will be addressed in a survey to explore the weight loss journey, barriers and management.
- Trial name
- NCT05736120
- Testing
- No treatment given
- Where
- India
- Volunteers
- 46 people
- Sponsor
- Novo Nordisk A/S
Leptin Receptor Deficiency Obesity
Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity
To demonstrate statistically significant and clinically meaningful effects of setmelanotide on percent body weight change in participants with LEPR deficiency obesity due to rare bi-allelic or loss-of function mutations at the…
- Trial name
- NCT03287960
- Testing
- Setmelanotide
- Where
- 6 sites in Canada, France and 4 more
- Volunteers
- 15 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Tachycardia Atrial, Atrial Fibrillation
BIO|STREAM.ICM Obesity
The aim of the submodule study is to assess whether a high BMI may influence the sensing performance and the sECG quality of the BIOMONITOR.
- Conditions
- Tachycardia Atrial, Atrial Fibrillation, Syncope, Bradycardia
- Trial name
- NCT04198220
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Biotronik SE & Co. KG
Overweight, Obese
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RM-493 Administered to Healthy, Obese, Non-diabetic Volunteers
The purpose of this study is to evaluate the multiple dose safety and tolerability of RM-493 (setmelanotide) as well as pharmacokinetic (PK) and pharmacodynamic (PD; weight loss) profile, in healthy obese patients for 2 to 4…
- Trial name
- NCT02431442
- Testing
- RM-493
- Volunteers
- 57 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Obesity
Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet (RCD) in Obese Subjects
To evaluate the weight loss effect and safety of 400 mg velneperit and 120 mg orlistat administered individually or combined three times per day for 24 weeks while on a reduced calorie diet (RCD) and also to evaluate the…
- Trial name
- NCT01126970
- Testing
- Velneperit 400 mg, Orlistat 120 mg, Reduced Calorie Diet
- Where
- 25 sites in United States
- Volunteers
- 486 people
- Sponsor
- Shionogi
Obese
Pharmacodynamics and Pharmacokinetics of Different Glucose Bead Formulations in Obese Healthy Subjects
The goal of this clinical study was to assess pharmacodynamics (PD) and pharmacokinetics (PK) of different Glucose beads formulations in obese healthy subjects under fasting condition. The study was designed in 2 parts.
- Trial name
- NCT05737927
- Testing
- Glucose 8 g coated beads (47% w/w), Glucose 12 g coated beads (47% w/w), Glucose 16 g coated beads (47% w/w)
- Where
- Romania
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Aphaia Pharma US LLC
Obesity
A Study of MK0364 in Obese Patients (0364-014)
A worldwide study in obese patients to assess the efficacy, safety, and tolerability of an investigational drug.
- Trial name
- NCT00131391
- Testing
- Comparator: taranabant
- Volunteers
- 2,400 people
- Sponsor
- Merck Sharp & Dohme LLC
Obesity, Overweight
A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects
The purpose of this study is to determine whether 2 doses of the combination of naltrexone SR and bupropion SR are safe and effective in the treatment of obesity.
- Trial name
- NCT00532779
- Testing
- Naltrexone SR 16 mg/Bupropion SR 360 mg /day, Naltrexone SR 32 mg/Bupropion SR 360 mg /day, Ancillary therapy
- Where
- 34 sites in United States
- Volunteers
- 1,742 people
- Sponsor
- Orexigen Therapeutics, Inc
Obesity, Overweight
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA)…
- Conditions
- Obesity, Overweight, Osteoarthritis, Knee, Obstructive Sleep Apnea
- Trial name
- TRIUMPH-1 (NCT05929066)
- Testing
- Retatrutide
- Where
- 134 sites in United States, Australia and 10 more
- Volunteers
- 2,335 people
- Sponsor
- Eli Lilly and Company
Esophageal Motility Disorders
Esophageal Dysmotility and Dilatation After Laparoscopic Gastric Banding
The purpose of this study is to determine whether esophageal dysmotility and dilatation is an important complication in the long term follow-up following laparoscopic gastric banding for morbid obesity.
- Trial name
- NCT01234428
- Testing
- Laparoscopic surgery, gastric banding
- Where
- Switzerland
- Volunteers
- 167 people
- Sponsor
- Spital STS AG
Obesity, Overweight
A Safety and Efficacy Study of HPP404 on Weight Loss in Overweight or Obese Subjects
The purpose of this study is to compare the safety and effect of HPP404 versus placebo on body weight in overweight or obese subjects.
- Trial name
- NCT01540864
- Testing
- HPP404
- Where
- 10 sites in United States
- Volunteers
- 126 people
- Sponsor
- High Point Pharmaceuticals, LLC.
Metabolism and Nutrition Disorder, Obesity
Awareness, Care & Treatment in Obesity Management (ACTION) Study
The ACTION (Awareness, Care, and Treatment In Obesity management) study aims to identify perceptions, attitudes, behaviours, and potential barriers to effective obesity care across three respondent types: 1) People with Obesity…
- Trial name
- ACTION (NCT03223493)
- Testing
- No treatment given
- Where
- United States
- Volunteers
- 3,767 people
- Sponsor
- Novo Nordisk A/S
Metabolism and Nutrition Disorder, Obesity
First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Male Subjects With Overweight or Obesity
This trial is conducted in The United States of America. The aim of this trial is to investigate Safety, Tolerability and Pharmacokinetics (the exposure of the trial drug in the body) of NNC0194-0499 in Male Subjects with…
- Trial name
- NCT03015207
- Testing
- NNC0194-0499
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Novo Nordisk A/S
Obesity & Overweight
Evaluation of a Mobile Wellness Application and Wearable Fitness Tracker on Weight Management and Health Outcomes
This randomized controlled trial aims to evaluate the effectiveness of a mobile wellness application, both alone and in combination with a wearable fitness tracker, for supporting weight management, physical activity, and mental…
- Trial name
- NCT07463144
- Testing
- App + Fitness Tracker, App Only, Control Group
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- BetterMe Limited
Diabetes Mellitus, Type 2, Overweight
A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus
The purpose of this study is to evaluate how fasting and stopping the use of tirzepatide affects the amount of food and drink that stays in the stomach after a meal.
- Conditions
- Diabetes Mellitus, Type 2, Overweight, Obesity
- Trial name
- NCT07299084
- Testing
- Tirzepatide
- Where
- Singapore
- Volunteers
- 40 people
- Sponsor
- Eli Lilly and Company
Obesity Associated With Defects in Leptin-melanocortin Pathway
Long Term Extension Trial of Setmelanotide
This was a long-term extension trial to study the safety and tolerability of continued setmelanotide treatment in participants who had completed a previous clinical trial on treatment with setmelanotide for obesity associated…
- Trial name
- NCT03651765
- Testing
- Setmelanotide
- Where
- 27 sites in United States, Canada and 6 more
- Volunteers
- 205 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Obesity
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 in Healthy Overweight/Obese Volunteers
This is a multiple dose study to evaluate the safety, tolerability, PK, and PD of K-757 alone, in combination with sitagliptin, or in combination with K-833.
- Trial name
- NCT05900531
- Testing
- K-757, K-757 and open-label sitagliptin, K-757 and K-833
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- TriGemX Bio, Inc.
Non-Alcoholic Fatty Liver Disease
ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)
The purpose of the study is to assess the safety and tolerability of ALT-801 in diabetic and non-diabetic subjects with overweight and obese and non-alcoholic fatty liver disease (NAFLD).
- Trial name
- NCT05006885
- Testing
- ALT-801
- Where
- 15 sites in United States
- Volunteers
- 95 people
- Sponsor
- Altimmune, Inc.
Obesity &Amp; Overweight, Chronic Kidney Disease
UBT251 Injection Phase II Clinical Study (CKD)
This multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of UBT251 injection in obese/overweight chronic kidney disease (CKD) population
- Trial name
- NCT07134335
- Testing
- UBT251
- Where
- China
- Volunteers
- 180 people
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.